Ampio Pharma - AMPE STOCK NEWS

Ampio Pharmaceuticals (NYSE American: AMPE) provided a business update and third-quarter financial results on November 5, 2020. The company reported an increase in cash to $9.4 million, compared to $6.5 million at the end of 2019. Research and development costs declined by 52% to $1.7 million, while general and administrative costs also fell by 5.6%. Ampio incurred a net loss of $3.4 million, down from $7.2 million year-over-year. Key developments include ongoing clinical trials for COVID-19 therapies and adjustments to the OAK Phase III trial due to the pandemic.

Ampio Pharmaceuticals (NYSE American: AMPE) announced a business and financial update webinar on November 5, 2020, at 4:30 PM EST. Key attendees include President and CEO Michael Macaluso, Founder Dr. David Bar-Or, VP Laura Goldberg, and CFO Daniel Stokely. The webinar will feature updates on COVID-19 platforms and the OAK Trial, alongside Q3 financial insights. Participants can access the webinar through a provided link and submit questions via phone or the platform. A replay will be available shortly after the call.

Ampio Pharmaceuticals (AMPE) has initiated a Phase I trial to evaluate the safety and efficacy of inhaled Ampion for COVID-19 patients suffering respiratory distress. The trial will involve 40 patients and will compare Ampion combined with standard care versus standard care alone. Dosing begins at Penrose Hospital, Colorado Springs, with assessments focusing on safety and secondary efficacy endpoints. The FDA has granted two INDs for inhalation and intravenous use of Ampion, supporting its potential as a platform drug for various inflammatory conditions.

Ampio Pharmaceuticals, Inc. (AMPE) announced its participation at the ROTH Capital Healthcare Event, specifically the COVID-19 Therapeutics in Development webinar on October 28, 2020. This event replaces a previous announcement regarding the company’s involvement in the 2020 MedTech Innovation Forum. The webinar will focus on therapies in development for COVID-19, featuring sessions on immune modulators and antiviral agents. Ampio's future statements regarding therapeutic advancements and regulatory approvals remain forward-looking and subject to risks.

Ampio Pharmaceuticals (AMPE) announced its participation in the 2020 MedTech Innovation Forum on October 28. The presentation will focus on preliminary results from a randomized study assessing the efficacy of Ampion in hospitalized COVID-19 patients requiring supplemental oxygen. The study compared Ampion plus standard of care (SOC) against SOC alone and SOC with remdesivir. Results showed that Ampion improved average outcomes significantly, with a reduction of 3 points in the Ordinal Scale compared to lesser reductions in the other groups. The primary endpoint of safety also reported no drug-related adverse events.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the publication of a preprint report demonstrating that Ampion™ reduces pro-inflammatory cytokine release by modulating inflammatory transcription factors. The findings suggest Ampion suppresses crucial pathways, indicating its potential anti-inflammatory effects, particularly in conditions like severe COVID-19. The manuscript supports safety and tolerability observed in prior trials. Ampion has a robust patent portfolio and could receive 12-year FDA market exclusivity upon approval as a novel biologic.

Ampio Pharmaceuticals announced the FDA's approval of an Investigational New Drug (IND) for its inhalable treatment, Ampion, targeting respiratory distress caused by COVID-19. This follows a positive Phase I trial for intravenous Ampion. The new clinical trial will assess safety and efficacy among 40 hospitalized patients, with the inhalation method allowing for targeted lung treatment. Previous studies indicated that Ampion is safe for inhalation and effective in reducing tissue damage-related signaling proteins. Ampio aims to leverage Ampion's potential across multiple inflammatory conditions.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced the completion of a Phase I trial for intravenous Ampion™ targeting COVID-19 patients, led by Dr. Michael Roshon from Penrose-St. Francis Hospital. The trial results were featured in a FOX news segment titled "Colorado Drug shows promise against COVID-19". Ampion is being developed to address prevalent inflammatory conditions with limited treatment options, boasting a strong patent portfolio and potential FDA exclusivity upon approval. For more details, view the full news segment at kdvr.com.

Ampio Pharmaceuticals, Inc. (AMPE) announced positive early trial results for intravenous Ampion treatment targeting COVID-19 patients. The Phase I trial involved hospitalized adults receiving supplemental oxygen and showed that IV Ampion met its primary safety endpoint, with no significant adverse events. Patients receiving Ampion exhibited stronger clinical improvements at discharge compared to the control group, which included standard care treatments. The company is set to proceed with further assessments and plans for a Phase II/III trial.